In-kind contributions provide services to nonprofits like the Sabin Vaccine Institute (Sabin) that would otherwise be unaffordable, freeing up scarce resources to be spent on our core mission – expanding the benefits of immunization around the world. Our work is benefited greatly by the in-kind support of Covington & Burling LLP, which has generously contributed more than a decade of pro-bono services valued at $1.6 million.

Over the past 10 years, Sabin has undergone significant strategic changes and growth, refining our mission to focus on making vaccines more accessible, enabling innovation and expanding immunization across the globe. We have relied upon the excellent attorneys and advisors at Covington & Burling to provide strategic advice, legal direction and guidance as we have grown and evolved.

Covington & Burling provided critical support to Sabin from 2010 to 2016 for programming related to the Global Network for Neglected Tropical Diseases (NTDs). They guided multiple agreements with partners – including celebrities Katie Perry and Ewan McGregor – as we launched and implemented the END7 campaign designed to end the seven most neglected tropical diseases. More recently, Covington & Burling assisted with the launch of our Vaccine Acceptance and Demand initiative in 2020 to promote vaccine confidence in communities throughout the world, which quickly adapted to help inform vaccine acceptance efforts for COVID-19 vaccines. They also supported partner agreements benefiting our advocacy and education efforts, such as our Surveillance for Enteric Fever in Asia Project (SEAP) to estimate the burden of typhoid in Bangladesh, Pakistan and Nepal to inform the introduction and implementation of control measures, including the new typhoid conjugate vaccine (TCV).

Covington & Burling’s support on agreements, contracts and documentation helped Sabin conduct human hookworm vaccine research and advance development of safe, effective and low-cost vaccines for some of the world’s most neglected diseases. Covington & Burling supported a strategy shift and the growth of Sabin’s R&D program to advance development of vaccines, including for Ebola Sudan and Marburg viruses that may protect more than 100 million people currently at risk.

While these are just a few examples, Covington & Burling has steadily and sure-footedly provided critical advice to Sabin for many years. We are immensely grateful.